Literature DB >> 8821644

Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers.

E L Hohmann1, C A Oletta, S I Miller.   

Abstract

Improved live oral typhoid fever vaccines may be engineered by deletion of Salmonella-specific virulence genes in Salmonella typhi. Ty445, an aroA-deleted S. typhi Ty2 strain also deleted for the phoP/phoQ Salmonella typhimurium virulence regulatory locus, was tested in human volunteers. Volunteers received escalating single doses of the vaccine; subsequently 14 individuals received two doses of 10(10) c.f.u. without significant side-effects. Control vaccinees received four doses of the live oral typhoid vaccine Ty21a. Of controls, 5/8 seroconverted as measured by increases in serum IgG directed against S. typhi O antigen or whole bacterial antigens in ELISAs. Only 2/14 volunteers receiving the experimental vaccine Ty445 seroconverted. Although a delta aroA delta phoP/phoQ S. typhi strain is overattenuated for use as a typhoid fever vaccine, our data demonstrate that the deletion of the phoP/phoQ locus in S. typhi significantly attenuates this human pathogen.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8821644     DOI: 10.1016/0264-410x(95)00173-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  41 in total

1.  Vaccines against gut pathogens.

Authors:  P Mastroeni; F Bowe; R Cahill; C Simmons; G Dougan
Journal:  Gut       Date:  1999-11       Impact factor: 23.059

Review 2.  Enteric pathogens as vaccine vectors for foreign antigen delivery.

Authors:  Camille N Kotton; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

3.  Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.

Authors:  J Y Wang; M F Pasetti; F R Noriega; R J Anderson; S S Wasserman; J E Galen; M B Sztein; M M Levine
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 4.  Developing live vaccines against plague.

Authors:  Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  J Infect Dev Ctries       Date:  2011-09-14       Impact factor: 0.968

Review 5.  New technologies in developing recombinant attenuated Salmonella vaccine vectors.

Authors:  Shifeng Wang; Qingke Kong; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-11-08       Impact factor: 3.738

6.  Keratinocyte growth factor gene therapy ameliorates ulcerative colitis in rats.

Authors:  Chun-Jie Liu; Ji-De Jin; Tong-De Lv; Zu-Ze Wu; Xiao-Qin Ha
Journal:  World J Gastroenterol       Date:  2011-06-07       Impact factor: 5.742

7.  Infection with an avirulent phoP mutant of Neisseria meningitidis confers broad cross-reactive immunity.

Authors:  J Newcombe; L-J Eales-Reynolds; L Wootton; A R Gorringe; S G P Funnell; S C Taylor; J J McFadden
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Generation of specific effector and memory T cells with gut- and secondary lymphoid tissue- homing potential by oral attenuated CVD 909 typhoid vaccine in humans.

Authors:  R Wahid; R Salerno-Gonçalves; C O Tacket; M M Levine; M B Sztein
Journal:  Mucosal Immunol       Date:  2008-07-02       Impact factor: 7.313

9.  Evaluation of regulated delayed attenuation strategies for Salmonella enterica serovar Typhi vaccine vectors in neonatal and infant mice.

Authors:  Huoying Shi; Shifeng Wang; Roy Curtiss
Journal:  Clin Vaccine Immunol       Date:  2013-04-24

10.  Live recombinant Salmonella Typhi vaccines constructed to investigate the role of rpoS in eliciting immunity to a heterologous antigen.

Authors:  Huoying Shi; Javier Santander; Karen E Brenneman; Soo-Young Wanda; Shifeng Wang; Patti Senechal; Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  PLoS One       Date:  2010-06-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.